Amid concerns of COVID-19 vaccine nationalism, Germany takes €300M stake in CureVac

Less than three months after media reports suggested the U.S. had attempted to gain exclusive rights to a COVID-19 vaccine from CureVac, the German government is taking the extraordinary step of making its first direct investment in a biotech company.

Germany’s €300 million ($337.3 million) stake in CureVac comes as the Tübingen-based mRNA company prepares to start clinical testing of the vaccine this month...